0001011060 2024-04-01 2024-09-30 0001011060 dei:BusinessContactMember 2024-04-01 2024-09-30 0001011060 2024-03-31 0001011060 2023-03-31 0001011060 us-gaap:RelatedPartyMember 2024-03-31 0001011060 us-gaap:RelatedPartyMember 2023-03-31 0001011060 2024-09-30 0001011060 us-gaap:RelatedPartyMember 2024-09-30 0001011060 NORD:ReverseStockSplitMember 2024-09-30 0001011060 NORD:ReverseStockSplitMember 2024-03-31 0001011060 2023-04-01 2024-03-31 0001011060 2022-04-01 2023-03-31 0001011060 2024-07-01 2024-09-30 0001011060 2023-07-01 2023-09-30 0001011060 2023-04-01 2023-09-30 0001011060 us-gaap:CommonStockMember 2022-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2022-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2022-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001011060 us-gaap:RetainedEarningsMember 2022-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2022-03-31 0001011060 NORD:CommonStockToBeIssuedMember 2022-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001011060 NORD:TotalEquityAttributedToParentMember 2022-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2022-03-31 0001011060 2022-03-31 0001011060 us-gaap:CommonStockMember 2023-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001011060 us-gaap:RetainedEarningsMember 2023-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2023-03-31 0001011060 NORD:CommonStockToBeIssuedMember 2023-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001011060 NORD:TotalEquityAttributedToParentMember 2023-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:CommonStockMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:RetainedEarningsMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:TreasuryStockCommonMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember NORD:CommonStockToBeIssuedMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember NORD:TotalEquityAttributedToParentMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:NoncontrollingInterestMember 2024-03-31 0001011060 us-gaap:CommonStockMember 2024-06-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-06-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001011060 us-gaap:RetainedEarningsMember 2024-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-06-30 0001011060 NORD:CommonStockToBeIssuedMember 2024-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001011060 NORD:TotalEquityAttributedToParentMember 2024-06-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-06-30 0001011060 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:CommonStockMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:RetainedEarningsMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:TreasuryStockCommonMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember NORD:CommonStockToBeIssuedMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001011060 NORD:ReverseStockSplitMember 2023-03-31 0001011060 us-gaap:CommonStockMember 2023-06-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-06-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001011060 us-gaap:RetainedEarningsMember 2023-06-30 0001011060 us-gaap:TreasuryStockCommonMember 2023-06-30 0001011060 NORD:CommonStockToBeIssuedMember 2023-06-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001011060 2023-06-30 0001011060 us-gaap:CommonStockMember 2022-04-01 2023-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2022-04-01 2023-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2022-04-01 2023-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2023-03-31 0001011060 us-gaap:RetainedEarningsMember 2022-04-01 2023-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2022-04-01 2023-03-31 0001011060 NORD:CommonStockToBeIssuedMember 2022-04-01 2023-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2023-03-31 0001011060 NORD:TotalEquityAttributedToParentMember 2022-04-01 2023-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2022-04-01 2023-03-31 0001011060 us-gaap:CommonStockMember 2023-04-01 2024-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-04-01 2024-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-04-01 2024-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2024-03-31 0001011060 us-gaap:RetainedEarningsMember 2023-04-01 2024-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2023-04-01 2024-03-31 0001011060 NORD:CommonStockToBeIssuedMember 2023-04-01 2024-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2024-03-31 0001011060 NORD:TotalEquityAttributedToParentMember 2023-04-01 2024-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2023-04-01 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember NORD:CommonStockToBeIssuedMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember NORD:TotalEquityAttributedToParentMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001011060 NORD:ReverseStockSplitMember 2024-04-01 2024-06-30 0001011060 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001011060 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001011060 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001011060 NORD:CommonStockToBeIssuedMember 2024-07-01 2024-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001011060 NORD:TotalEquityAttributedToParentMember 2024-07-01 2024-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001011060 NORD:ReverseStockSplitMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember NORD:CommonStockToBeIssuedMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001011060 NORD:ReverseStockSplitMember 2023-04-01 2023-06-30 0001011060 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001011060 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001011060 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001011060 NORD:CommonStockToBeIssuedMember 2023-07-01 2023-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001011060 us-gaap:CommonStockMember 2024-03-31 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-03-31 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001011060 us-gaap:RetainedEarningsMember 2024-03-31 0001011060 us-gaap:TreasuryStockCommonMember 2024-03-31 0001011060 NORD:CommonStockToBeIssuedMember 2024-03-31 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001011060 NORD:TotalEquityAttributedToParentMember 2024-03-31 0001011060 us-gaap:NoncontrollingInterestMember 2024-03-31 0001011060 us-gaap:CommonStockMember 2024-09-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2024-09-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2024-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001011060 us-gaap:RetainedEarningsMember 2024-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2024-09-30 0001011060 NORD:CommonStockToBeIssuedMember 2024-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001011060 NORD:TotalEquityAttributedToParentMember 2024-09-30 0001011060 us-gaap:NoncontrollingInterestMember 2024-09-30 0001011060 us-gaap:CommonStockMember 2023-09-30 0001011060 NORD:SeriesAJuniorMember us-gaap:PreferredStockMember 2023-09-30 0001011060 NORD:PreferredStockUndesignatedMember us-gaap:PreferredStockMember 2023-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001011060 us-gaap:RetainedEarningsMember 2023-09-30 0001011060 us-gaap:TreasuryStockCommonMember 2023-09-30 0001011060 NORD:CommonStockToBeIssuedMember 2023-09-30 0001011060 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001011060 2023-09-30 0001011060 NORD:AssetPurchaseAgreementMember 2020-01-27 2020-01-31 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2021-10-11 2021-10-12 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-10 2022-03-11 0001011060 NORD:FirstClosingMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-10 2022-03-11 0001011060 NORD:SecondClosingMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-14 2022-03-15 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 0001011060 NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-14 2022-03-15 0001011060 NORD:ContributionAgreementMember 2023-02-21 2023-02-23 0001011060 NORD:ContributionAgreementMember 2023-02-23 0001011060 NORD:NordicusPartnersAsMember NORD:ContributionAgreementMember 2023-02-23 0001011060 NORD:MagMileCapitalIncMember 2023-06-01 0001011060 NORD:OrocidinASMember us-gaap:SubsequentEventMember 2024-05-16 0001011060 NORD:ReverseStockSplitMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2021-10-11 2021-10-12 0001011060 NORD:FirstClosingMember NORD:ReverseStockSplitMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-10 2022-03-11 0001011060 NORD:SecondClosingMember NORD:ReverseStockSplitMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-14 2022-03-15 0001011060 NORD:ReverseStockSplitMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2022-03-15 0001011060 NORD:ContributionAgreementMember 2023-02-23 2023-02-23 0001011060 NORD:OrocidinASMember 2023-02-23 0001011060 us-gaap:CommonStockMember NORD:OrocidinASMember 2024-05-13 2024-05-13 0001011060 us-gaap:RestrictedStockMember NORD:OrocidinASMember 2024-05-13 2024-05-13 0001011060 2024-11-08 2024-11-08 0001011060 2024-11-08 0001011060 NORD:OrocidinASMember 2024-06-03 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember NORD:MysonIncMember 2023-06-19 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember 2023-06-19 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember NORD:MysonIncMember 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2023-06-19 2023-06-20 0001011060 NORD:ReverseStockSplitMember NORD:GKPartnersMember 2023-06-19 2023-06-20 0001011060 us-gaap:RestrictedStockMember NORD:GKPartnersMember NORD:MagMileCapitalIncMember 2023-06-20 0001011060 NORD:GKPartnersMember 2022-04-11 0001011060 NORD:GKPartnersMember 2023-02-14 2023-02-14 0001011060 NORD:GKPartnersMember 2023-02-14 0001011060 NORD:GKPartnersMember 2023-06-26 2023-06-26 0001011060 NORD:GKPartnersMember 2023-06-26 0001011060 NORD:GKPartnersMember 2023-07-26 2023-07-26 0001011060 NORD:GKPartnersMember 2023-07-26 0001011060 NORD:GKPartnersMember 2023-08-24 2023-08-24 0001011060 NORD:GKPartnersMember 2023-08-24 0001011060 NORD:GKPartnersMember 2023-09-01 2023-09-30 0001011060 NORD:GKPartnersMember 2023-09-30 0001011060 NORD:GKPartnersMember 2023-10-01 2023-12-31 0001011060 NORD:GKPartnersMember 2023-12-31 0001011060 NORD:GKPartnersMember 2024-01-01 2024-03-31 0001011060 NORD:GKPartnersMember 2024-03-31 0001011060 NORD:MrBennettYankowitzMember 2023-04-01 2024-03-31 0001011060 NORD:MrBennettYankowitzMember 2022-04-01 2023-03-31 0001011060 NORD:MrBennettYankowitzMember 2024-03-31 0001011060 NORD:MrBennettYankowitzMember 2023-03-31 0001011060 NORD:GKPartnersMember 2023-03-31 0001011060 NORD:HenrikRoufMember 2023-04-16 2023-04-17 0001011060 NORD:HenrikRoufMember us-gaap:SubsequentEventMember 2024-04-08 2024-04-08 0001011060 NORD:MrBennettYankowitzMember 2023-04-16 2023-04-17 0001011060 NORD:MrBennettYankowitzMember us-gaap:SubsequentEventMember 2024-04-08 2024-04-08 0001011060 NORD:ReverseStockSplitMember NORD:GKPartnersMember 2022-04-11 0001011060 NORD:ReverseStockSplitMember NORD:GKPartnersMember 2023-12-22 0001011060 NORD:GKPartnersMember 2023-12-22 0001011060 NORD:ReverseStockSplitMember NORD:GKPartnersMember 2023-04-01 2024-03-31 0001011060 NORD:ReverseStockSplitMember NORD:GKPartnersMember 2024-03-31 0001011060 NORD:GKPartnersMember 2023-04-01 2024-03-31 0001011060 NORD:GKPartnersMember 2024-04-01 2024-06-30 0001011060 NORD:GKPartnersMember 2024-06-30 0001011060 NORD:GKPartnersMember 2024-07-01 2024-09-30 0001011060 NORD:GKPartnersMember us-gaap:WarrantMember 2024-09-30 0001011060 NORD:GKPartnersMember us-gaap:WarrantMember 2024-07-01 2024-09-30 0001011060 NORD:MrBennettYankowitzMember 2024-07-01 2024-09-30 0001011060 NORD:MrBennettYankowitzMember 2023-07-01 2023-09-30 0001011060 NORD:MrBennettYankowitzMember 2024-04-01 2024-09-30 0001011060 NORD:MrBennettYankowitzMember 2023-04-01 2023-09-30 0001011060 NORD:MrBennettYankowitzMember 2024-09-30 0001011060 NORD:HenrikRoufMember 2023-04-01 2023-04-01 0001011060 NORD:HenrikRoufMember 2024-04-08 2024-04-08 0001011060 NORD:MrBennettYankowitzMember 2023-04-01 2023-04-01 0001011060 NORD:MrBennettYankowitzMember 2024-04-08 2024-04-08 0001011060 srt:BoardOfDirectorsChairmanMember 2024-06-03 2024-06-03 0001011060 srt:DirectorMember 2024-06-03 2024-06-03 0001011060 NORD:SeriesAJuniorParticipatingPreferredStockMember 2024-03-31 0001011060 NORD:SeriesAJuniorParticipatingPreferredStockMember 2024-09-30 0001011060 us-gaap:PreferredStockMember 2024-09-30 0001011060 us-gaap:PreferredStockMember 2024-03-31 0001011060 NORD:GKPartnersMember 2023-06-19 2023-06-20 0001011060 NORD:GKPartnersMember 2023-06-20 0001011060 us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001011060 NORD:GKPartnersMember 2024-04-01 2024-09-30 0001011060 NORD:GKPartnersMember 2024-09-30 0001011060 NORD:OrocidinASMember us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001011060 NORD:OrocidinASMember 2024-09-30 0001011060 NORD:OrocidinASMember us-gaap:NoncontrollingInterestMember 2024-04-01 2024-09-30 0001011060 NORD:OrocidinASMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-09-30 0001011060 NORD:GKPartnersMember us-gaap:WarrantMember 2022-04-11 0001011060 NORD:GKPartnersMember us-gaap:WarrantMember 2022-04-11 2022-04-11 0001011060 NORD:GKPartnersMember 2022-04-01 2023-03-31 0001011060 NORD:GKPartnersMember 2023-12-21 2023-12-22 0001011060 NORD:DavidVolpeMember 2022-11-28 0001011060 NORD:MrBennettYankowitzMember 2022-11-28 0001011060 NORD:VolpeAndYankowitzMember 2022-11-28 0001011060 NORD:VolpeAndYankowitzMember us-gaap:WarrantMember 2022-11-28 0001011060 NORD:VolpeAndYankowitzMember us-gaap:WarrantMember 2022-11-28 2022-11-28 0001011060 NORD:VolpeAndYankowitzMember 2022-04-01 2023-03-31 0001011060 us-gaap:WarrantMember 2023-03-31 0001011060 us-gaap:WarrantMember 2022-04-01 2023-03-31 0001011060 us-gaap:WarrantMember 2023-04-01 2024-03-31 0001011060 us-gaap:WarrantMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:WarrantMember 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:WarrantMember 2023-04-01 2024-03-31 0001011060 NORD:ReverseStockSplitMember us-gaap:WarrantMember 2024-04-01 2024-09-30 0001011060 NORD:ReverseStockSplitMember us-gaap:WarrantMember 2024-09-30 0001011060 us-gaap:SubsequentEventMember NORD:GKPartnersMember 2024-04-29 2024-04-29 0001011060 us-gaap:SubsequentEventMember NORD:GKPartnersMember 2024-04-29 0001011060 us-gaap:CommonStockMember us-gaap:SubsequentEventMember NORD:OrocidinASMember 2024-05-13 2024-05-13 0001011060 us-gaap:RestrictedStockMember NORD:OrocidinASMember us-gaap:SubsequentEventMember 2024-05-13 2024-05-13 0001011060 us-gaap:SubsequentEventMember NORD:GKPartnersMember 2024-05-30 2024-05-30 0001011060 us-gaap:SubsequentEventMember NORD:GKPartnersMember 2024-05-30 0001011060 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2024-06-03 2024-06-03 0001011060 srt:DirectorMember us-gaap:SubsequentEventMember 2024-06-03 2024-06-03 0001011060 NORD:TwentyTwentyFourStockIncentivePlanMember us-gaap:SubsequentEventMember 2024-06-07 0001011060 us-gaap:SubsequentEventMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2024-11-08 2024-11-08 0001011060 us-gaap:SubsequentEventMember NORD:StockPurchaseAgreementMember NORD:ReddingtonPartnersLLCMember 2024-11-08 0001011060 NORD:GKPartnersMember 2024-10-01 2024-11-14 0001011060 NORD:GKPartnersMember 2024-11-14 0001011060 NORD:RestrictedCommonStockMember us-gaap:SubsequentEventMember 2024-11-11 2024-11-11 0001011060 us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001011060 us-gaap:SubsequentEventMember 2024-11-12 0001011060 us-gaap:CommonStockMember 2024-06-07 0001011060 us-gaap:EmployeeStockOptionMember 2024-06-07 0001011060 us-gaap:RestrictedStockMember 2024-06-07 0001011060 NORD:TwoThousandSeventeenPlanMember 2024-06-17 2024-06-17 0001011060 NORD:DanishStockCorporationMember 2024-05-13 2024-05-13 0001011060 NORD:DanishStockCorporationMember 2024-05-13 0001011060 NORD:OrocidinASMember 2024-05-13 2024-09-30 iso4217:USD shares iso4217:USD shares pure false 0001011060

S-1 NORDICUS PARTNERS CORPORATION DE 04-3186647 280 South Beverly Dr. Suite 505 Beverly Hills CA 90212 (310) 666-0750 Henrik Rouf 280 South Beverly Dr. Suite 505 Beverly Hills CA 90212 (310) 666-0750 Non-accelerated Filer true false

49933

7149

44481

770

49933

52400

7640 2625

1750000

1807573

55025

5019

1354

12127

7500

13886

26405

27367

26405

27367

0.001

5000000

0.001

50000000

1110226

829626

1110

830

154

30328

45696761

42254154

-2848

665

-43883527

-42197663

1781168

27658

1781168

27658

1807573

55025

2500

118477

8141501

137280

102286

39602

54331

196500

310088

8479889

-307588

-8479889

382

9386

8055

9386

7673

-298202

-8472216

-298202

-8472216

-3513

665

-301715

-8471551

-0.29

-14.27

1035475

593886

568126

568

33949718

-33725447

-30328

194511

8141501 8141501

250000

250

47947

48197

11500 12 114988 115000

-8472216

665

-8471551

829626

830

42254154

-42197663

-30328

665

27658

829626

830

42254154

-42197663

-30328

665

27658

250000

250

1749750

1750000

30600 30 305970 306000

1387662

-1387662

-775

-298202

-3513

-301715

1110226

1110

45696761

-43883527

-30328

-2848

1781168

1110226

1110

45696761

-43883527

-30328

-2848

1781168

-298202

-8472216

8141501

4245

-3500

-44481

7500

-12127

3665

-41132

-258928

-368347

775

40000

13886

306000

115000

305225

128886

46297

-239461

-3513

665

7149

245945

49933

7149

1387662

1750000

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Nordicus Partners Corporation (the “Company” or “Nordicus”) was founded in 1993 as a subsidiary of PolyMedica Corporation. On January 31, 2020, we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provided critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states. As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify either an (i) operating company to acquire or merge with through an equity-based exchange transaction or (ii) investor interested in purchasing a majority interest in our common stock, whereby either transaction would likely result in a change in control. On March 3, 2020, we filed a Certificate of Amendment to the Company’s Certificate of Incorporation, which amendment was unanimously approved by our Board of Directors, to change our name AdvanSource Biomaterials Corporation to EKIMAS Corporation. On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”) providing for the purchase of a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211011__20211012__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zBtZlFfdbFK">511,448 of our common stock, on a post-split basis, or approximately <span id="xdx_904_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20211011__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zdJAtMlIHRQd" title="Percentage of outstanding shares">90% of our total shares of common stock outstanding for total cash consideration of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211011__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zQru6cgpguy3">400,000. Reddington purchased in two tranches on October 12, 2021 and March 15, 2022. Pursuant to the SPA, the Company effectuated a <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220310__20220311__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zG3kl4tX2UXl">1-for 50 reverse stock split on March 11, 2022 (the “Reverse Split”). Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220310__20220311__srt--StatementScenarioAxis__custom--FirstClosingMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z9AA0s2keOp8">42,273 shares of our common stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220314__20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__srt--StatementScenarioAxis__custom--SecondClosingMember_zoSqEeEGRm6d">469,175 shares of our common stock, on a post-split basis (the “Second Closing”). After the issuance thereof Reddington owned <span id="xdx_90A_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zzyU6NEpkyff">511,448 shares of our common stock, or approximately <span id="xdx_90B_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20220314__20220315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z1P3y0P0izXe" title="Percentage of outstanding shares">90% of our total shares of common stock outstanding. On February 23, 2023, the Company and Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S), a Danish stock corporation, consummated the transactions contemplated by that certain Contribution Agreement (the “Contribution Agreement”) by and among the Company, Nordicus, GK Partners, Henrik Rouf and Life Science Power House ApS (“LSPH”). (GK Partners, Rouf and LSPH are collectively referred to herein as the “Sellers”, and each individually as a “Seller”). Pursuant to the Contribution Agreement the Sellers contributed, transferred, assigned and conveyed to the Company all right, title and interest in and to one hundred percent (<span id="xdx_901_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20230221__20230223__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_zP8BwLml1pKl" title="Percentage of outstanding shares">100%) of the issued and outstanding capital stock of Nordicus for an aggregate of 250,000 shares of the Company’s common stock, par value $0.001 per share. As a result of this transaction, Nordicus became a <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NordicusPartnersAsMember__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_zPumWyCdxr32">100% wholly owned subsidiary of the Company. On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On June 9, 2023, Tom Glaesner Larsen resigned from the Company’s board of directors, and the remaining board members appointed Henrik Keller as his replacement. On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. On June 1, 2023, the Company acquired a 4.99% interest in Mag Mile Capital, Inc., a full-service commercial real estate mortgage banking firm headquartered in Chicago with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs. On May 16, 2024, we acquired a <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20240516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zKfoByxI6Kp9" title="Equity interest acquired, percentage">95% interest in Orocidin A/S, a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies.

7250000

511448

0.90

400000

1-for 50 reverse stock split

42273

469175

511448

0.90 1

250000

0.001

0.0499

0.95

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the collectability of receivables, useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill. Concentration of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of March 31, 2024 and 2023. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Managementselskabet af 12.08.2020 A/S. All significant intercompany transactions have been eliminated in consolidation. Translation Adjustment The accounts of the Company’s subsidiary are maintained in Danish krone. According to the Codification, all assets and liabilities were translated at the current exchange rate at respective balance sheets dates, members’ capital are translated at the historical rates and income statement items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with the Comprehensive Income Topic of the Codification (ASC 220), as a component of Stockholders’ equity. Transaction gains and losses are reflected in the income statement. Comprehensive Income The Company uses SFAS 130 “Reporting Comprehensive Income” (ASC Topic 220). Comprehensive income is comprised of net income and all changes to the statements of Stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income is included in net loss and foreign currency translation adjustments. Stock-based Compensation In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 allows companies to account for nonemployee awards in the same manner as employee awards. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity of those instruments. The Company’s notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements on March 31, 2024 and 2023. Net Income (Loss) Per Common Share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. As of March 31, 2024 and 2023, there were 632,900 and 663,500 potentially dilutive shares of common stock from warrants, respectively. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share. Income Taxes Income taxes are provided for the tax effects of the transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to tax net operating loss carryforwards. The deferred tax assets and liabilities represent the future tax return consequences of these differences, which will either be taxable or deductible when assets and liabilities are recovered or settled, as well as operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established against deferred tax assets when in the judgment of management, it is more likely than not that such deferred tax assets will not become available. Because the judgment about the level of future taxable income is dependent to a great extent on matters that may, at least in part, be beyond the Company’s control, it is at least reasonably possible that management’s judgment about the need for a valuation allowance for deferred taxes could change in the near term. Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of March 31, 2024, and 2023, no liability for unrecognized tax benefits was required to be reported. Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> In January 2024, the Company signed its first agreement for which it will recognize revenue. The revenue will be recognized over the one-year term of the contract, resulting in $2,500 of revenue for the year ended March 31, 2024 and $7,500 of deferred revenue as of March 31, 2024. Recently Issued Accounting Pronouncements The Company has implemented all new applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the collectability of receivables, useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill.

Concentration of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.

Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of March 31, 2024 and 2023.

Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Managementselskabet af 12.08.2020 A/S. All significant intercompany transactions have been eliminated in consolidation.

Translation Adjustment The accounts of the Company’s subsidiary are maintained in Danish krone. According to the Codification, all assets and liabilities were translated at the current exchange rate at respective balance sheets dates, members’ capital are translated at the historical rates and income statement items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with the Comprehensive Income Topic of the Codification (ASC 220), as a component of Stockholders’ equity. Transaction gains and losses are reflected in the income statement.

Comprehensive Income The Company uses SFAS 130 “Reporting Comprehensive Income” (ASC Topic 220). Comprehensive income is comprised of net income and all changes to the statements of Stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income is included in net loss and foreign currency translation adjustments.

Stock-based Compensation In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 allows companies to account for nonemployee awards in the same manner as employee awards. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods.

Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity of those instruments. The Company’s notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements on March 31, 2024 and 2023.

Net Income (Loss) Per Common Share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. As of March 31, 2024 and 2023, there were 632,900 and 663,500 potentially dilutive shares of common stock from warrants, respectively. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

632900

663500

Income Taxes Income taxes are provided for the tax effects of the transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to tax net operating loss carryforwards. The deferred tax assets and liabilities represent the future tax return consequences of these differences, which will either be taxable or deductible when assets and liabilities are recovered or settled, as well as operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established against deferred tax assets when in the judgment of management, it is more likely than not that such deferred tax assets will not become available. Because the judgment about the level of future taxable income is dependent to a great extent on matters that may, at least in part, be beyond the Company’s control, it is at least reasonably possible that management’s judgment about the need for a valuation allowance for deferred taxes could change in the near term. Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of March 31, 2024, and 2023, no liability for unrecognized tax benefits was required to be reported.

Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> In January 2024, the Company signed its first agreement for which it will recognize revenue. The revenue will be recognized over the one-year term of the contract, resulting in $2,500 of revenue for the year ended March 31, 2024 and $7,500 of deferred revenue as of March 31, 2024.

2500

7500

Recently Issued Accounting Pronouncements The Company has implemented all new applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN The Company’s financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has minimal revenue and has incurred losses since inception resulting in an accumulated deficit of $43,883,527 as of March 31, 2024. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, there is substantial doubt about the ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company’s recent acquisition, its generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

-43883527

NOTE 4 - INVESTMENTS On June 20, 2023, the Company and GK Partners ApS (the “Seller”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Seller sold to the Company <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MysonIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0zsLeMtqgnh">5,000,000 restricted shares of common stock of Mag Mile Capital, Inc. In exchange, the Company issued <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPoCZWc7rNw5">250,000 restricted shares of its common stock to the Seller. The shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MysonIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaz7KhG2qRO9">1,750,000, using $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MysonIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVkDiwn3BBc4">7.00 per share, the closing stock price for the Company’s common stock on the last business day before the agreement. The Company accounts for its investment under the guidance of ASC 321, Investments – Equity Securities, which provides guidance for equity interests that meet the definition of an equity security. Equity interests with readily determinable fair values are carried at fair value with changes in value recorded in earnings. There currently is no active market for the shares of Mag Mile Capital, Inc, therefore, the investment remains at cost until such time there is an established fair value of Mag Mile Capital, Inc’s shares to be used to adjust the value of the Company’s investment in those shares. The Company’s investment in Mag Mile Capital, Inc is subject to changes and fluctuations based on their business activities and their ability to trade in the future.

5000000

250000

1750000

7.00

NOTE 5 - RELATED PARTY TRANSACTIONS Mr. Tom Glasner Larsen is an affiliate of GK Partners and was a member of our board of directors from February 23, 2023, until his voluntary retirement on June 9, 2023. He was also a beneficial owner of a controlling interest in Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S) until its acquisition by us on February 23, 2023. On April 11, 2022, effective April 1, 2022, we issued to GK Partners, for financial services, a warrant to immediately purchase up to 600,000 shares of our common stock at an exercise price of $10.00 per share, which expires on December 31, 2023. On February 14, 2023, GK Partners exercised a portion of its warrant for 11,500 shares. The exercise price was $10.00 per share for total proceeds of $115,000. On June 26, 2023, GK Partners exercised a portion of its warrant for 2,500 shares. The exercise price was $10.00 per share for total proceeds of $25,000. On July 26, 2023, GK Partners exercised a portion of its warrant for 2,500 shares. The exercise price was $10.00 per share for total proceeds of $25,000. On August 24, 2023, GK Partners exercised a portion of its warrant for 3,000 shares. The exercise price was $10.00 per share for total proceeds of $30,000. During September 2023, GK Partners exercised a portion of its warrant for 2,500 shares. The exercise price was $10.00 per share for total proceeds of $25,000. During Q3 GK Partners exercised a portion of its warrant for 7,500 shares. The exercise price was $10.00 per share for total proceeds of $75,000. During Q4 GK Partners exercised a portion of its warrant for 12,600 shares. The exercise price was $10.00 per share for total proceeds of $126,000. On February 23, 2023, pursuant to the Contribution Agreement by and among the Company, Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S), GK Partners ApS (“GK Partners”), Henrik Rouf and Life Science Power House ApS (“LSPH”), were issued 250,000 shares of the common stock (Note 1). On June 20, 2023, the Company and GK Partners ApS (the “Seller”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Seller sold to the Company <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MysonIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z30Hezyg400a">5,000,000 restricted shares of common stock of Mag Mile Capital, Inc. In exchange, the Company issued <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRxwLjAuD4u">250,000 restricted shares of its common stock to the Seller. Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $17,022 and $35,415 for the year ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and 2023, we had a $0 and $6,574, respectively, payable due to the Affiliate. As of March 31, 2023, the Company had a receivable of $44,481, due from GK Partners. The amount was received in Q1 FY 2024. On April 17, 2023, our Board of Directors approved an employment agreement for our chief executive officer, Henrik Rouf, and a consulting agreement for our chief financial officer, Bennett J. Yankowitz. Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HenrikRoufMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9TsCmGJb3u" title="Salary payment">120,000 and to extend the term to <span id="xdx_90C_ecustom--EmploymentAgreementExpirationDate_pid_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HenrikRoufMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJeh64vdff29" title="Employment agreement expiration date">April 1, 2025. Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and had a term of <span id="xdx_904_ecustom--EmploymentAgreementTerm_dc_c20230416__20230417__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_z7pK7VSqS22f" title="Employment agreement term">one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $<span id="xdx_907_eus-gaap--OfficersCompensation_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfX59dzpqLK2" title="Base salary per year">60,000 and to extend the term to <span id="xdx_906_ecustom--EmploymentAgreementExpirationDate_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIbB0XffLxzb" title="Employment agreement expiration date">April 1, 2025.

600000

10.00

2023-12-31

11500

10.00

115000

2500

10.00

25000

2500

10.00

25000

3000

10.00

30000

2500

10.00

25000

7500

10.00

75000

12600

10.00

126000

250000

5000000

250000

17022

35415

6574

44481

72000

P1Y

120000

2025-04-01

36000

P1Y

60000

2025-04-01

NOTE 6 - PREFERRED STOCK Preferred Stock We have authorized 5,000,000 shares, $0.001 par value, Preferred Stock (the Preferred Stock”) of which 500,000 shares have been issued and redeemed, therefore are not considered outstanding. In addition, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zQhAQegsKC4b" title="Preferred stock shares authorized">500,000 shares of Preferred Stock have been designated as Series A Junior Participating Preferred Stock (the “Junior Preferred Stock”) with the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions specified in the Certificate of Designation of the Junior Preferred Stock filed with the Delaware Department of State on January 28, 2008. Such number of shares may be increased or decreased by resolution of the Board of Directors; provided, that no decrease shall reduce the number of shares of Junior Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by us that is convertible into Junior Preferred Stock. As of March 31, 2024 and 2023, there are no shares or Preferred Stock issued or outstanding.

5000000

0.001

500000

NOTE 7 - COMMON STOCK TRANSACTIONS During the year ended March 31, 2024, GK Partners exercised a portion of its warrant for 30,600 shares. The exercise price was $10.00 per share for total proceeds of $306,000. On June 20, 2023, the Company and GK Partners ApS entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Seller sold to the Company <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MysonIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3CoNJh8dqv3">5,000,000 restricted shares of common stock of Mag Mile Capital, Inc, Inc. In exchange, the Company issued <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgOizwR7Z403">250,000 restricted shares of its common stock to GK Partners. The shares were valued at $1,750,000, using $7.00 per share, the closing stock price on the last business day before the closing of the transaction under the Agreement.

30600

10.00

306000

5000000

250000

1750000

7.00

NOTE 8 - WARRANTS On April 11, 2022, effective April 1, 2022, we issued to GK Partners ApS, for financial services, a warrant to immediately purchase up to 600,000 shares of our common stock at an exercise price of $10.00 per share which expired on December 31, 2023. In determining the fair value of the warrant, we used the Black-Scholes pricing model having the following assumptions: (i) exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaCSAE26nGk7">10.00; (ii) fair market value of our common stock of $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2v4uBZJChdl">12.2 as quoted on the OTC Markets on the date of issuance of the Warrant; (iii) expected term of option of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220411__20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWVfJJh3Ug3b">1.75 years; (iv) expected volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220411__20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlrggLv4D6bd">699.79%; (v) expected dividend rate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220411__20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zciJz5CQm972">0.0%; and (vi) risk-free interest rate of approximately <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220411__20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0iXJEn8E1ri">2.44%. As a result, we recorded stock-based compensation of approximately $7,316,971 for the year ended March 31, 2023. On December 22, 2023, the expiration date of the 570,500 remaining warrants was extended to December 31, 2024. The Company revalued the 570,500 remaining warrants for the change in the expiration date resulting in the recognition of a deemed dividend of $1,387,662. On November 28, 2022, we issued 1) to David Volpe a warrant to purchase 50,000 shares of the Company’s Common Stock and 2) to Bennett J. Yankowitz a warrant to purchase 25,000 shares of the Company’s Common Stock. The warrants have an exercise price of $10.00 per share and expire on December 31, 2027. Mr. Volpe’s warrants were issued as compensation for consulting services provided to the Company. Mr. Yankowitz’s warrants were issued as compensation for his acting as the sole director and the chief executive officer of the Company. In determining the fair value of the warrants, we used the Black-Scholes pricing model having the following assumptions: (i) stock option exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221128__srt--TitleOfIndividualAxis__custom--VolpeAndYankowitzMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKR17R6CwHU5">10.00; (ii) fair market value of our common stock of $11.2 as quoted on the OTC Markets on the date of issuance of the Warrant; (iii) term of option of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221128__20221128__srt--TitleOfIndividualAxis__custom--VolpeAndYankowitzMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2aZEK8Nqs3">5 years; (iv) expected volatility of approximately <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221128__20221128__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--VolpeAndYankowitzMember_zGAlWOLaWewh">206%; (v) expected dividend rate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20221128__20221128__srt--TitleOfIndividualAxis__custom--VolpeAndYankowitzMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF6S70A0Wr9k">0.0%; and (vi) risk-free interest rate of approximately <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20221128__20221128__srt--TitleOfIndividualAxis__custom--VolpeAndYankowitzMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXwUYPfxwZMh">3.88%. As a result, we recorded total stock-based compensation of approximately $825,000 for the year ended March 31, 2023. SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Contract Term</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding, March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLDR1zUOzDmc" style="width: 11%; text-align: right" title="Number of Warrants, Beginning balance">663,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcqKE2c6k4Pf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">10.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0BWlQZtredg" title="Weighted Average Remaining Contractual term,Outstanding">1.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQXgkPKKfHb3" style="width: 11%; text-align: right" title="Intrinsic Value, Beginning balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCBGqpeWHv8g" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYo9IjgGNMp3" style="text-align: right" title="Number of Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmUZbymdbNrj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(30,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> —</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvZ7aIl0C5Cc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Ending balance">632,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlxeAkVLfMD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Ending balance">10.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQtrZFL14N4c" title="Weighted Average Remaining Contractual term,Outstanding">1.35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1lo9oLmeSK7" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value, Ending balance">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

600000

10.00

2023-12-31

10.00

12.2

P1Y9M

6.9979

0.000

0.0244

7316971

570500

2024-12-31

570500

1387662

50000

25000

10.00

2027-12-31

10.00

11.2

P5Y

2.06

0.000

0.0388

825000

SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Contract Term</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Intrinsic Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding, March 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLDR1zUOzDmc" style="width: 11%; text-align: right" title="Number of Warrants, Beginning balance">663,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcqKE2c6k4Pf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">10.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0BWlQZtredg" title="Weighted Average Remaining Contractual term,Outstanding">1.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQXgkPKKfHb3" style="width: 11%; text-align: right" title="Intrinsic Value, Beginning balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCBGqpeWHv8g" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYo9IjgGNMp3" style="text-align: right" title="Number of Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmUZbymdbNrj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(30,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"> —</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvZ7aIl0C5Cc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Ending balance">632,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlxeAkVLfMD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Ending balance">10.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQtrZFL14N4c" title="Weighted Average Remaining Contractual term,Outstanding">1.35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1lo9oLmeSK7" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic Value, Ending balance">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

663500

10.00 P1Y2M15D

30600

632900

10.00 P1Y4M6D

NOTE 9 – INCOME TAX Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated Staff Accounting Bulletin No. 118 regarding the impact of the decreased tax rates of the Tax Cuts & Jobs Act. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used. Reconciliation between our effective tax rate and the United States statutory rate is as follows: Significant components of our deferred tax assets and deferred tax liabilities consist of the following: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_491_20240331_zadfhB0Himng" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_498_20230331_zZQ9s6fuVbSb" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z5m11jxSLMf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTALNzpWI_zN6vyMpiB05a" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,375,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,313,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzpWI_zIC98giZDSn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,375,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,313,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTALNzpWI_zY6pTjL6M6qj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At March 31, 2024, the Company had net operating loss carry forwards of approximately $35,359,000 that may be offset against future taxable income. NOLs from tax years up to 2017 can be carried forward twenty years. Under the CARES Act, the Company can carry forward NOLs indefinitely for NOLs generated in a tax year beginning after 2017, that remain after they are carried back to tax years in the five-year carryback period. No tax benefit has been reported in the March 31, 2024, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2016.

0.21

Significant components of our deferred tax assets and deferred tax liabilities consist of the following: SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND DEFERRED TAX LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_491_20240331_zadfhB0Himng" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_498_20230331_zZQ9s6fuVbSb" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_404_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_z5m11jxSLMf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTALNzpWI_zN6vyMpiB05a" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,375,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,313,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzpWI_zIC98giZDSn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,375,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,313,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTALNzpWI_zY6pTjL6M6qj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2375300

2313000

2375300

2313000

35359000

NOLs from tax years up to 2017 can be carried forward twenty years

NOTE 10 - SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it has the following material subsequent events to disclose in these financial statements. On April 29, 2024, GK Partners exercised a portion of its warrant for <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240429__20240429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GKPartnersMember_zE9ZiTCGwkB">3,000 shares. The exercise price was $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240429__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GKPartnersMember_zeVaUo7yALqa">10.00 per share for total proceeds of $30,000. On May 13, 2024, the Company and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240513__20240513__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztq7XSWoez2">525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing <span id="xdx_902_ecustom--PercentageOfOutstandingCommonStock_dp_uPure_c20240513__20240513__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA4iLtszkcHe" title="Percentage of outstanding shares">95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240513__20240513__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zX6weggxVgxb">3,800,000 restricted shares of its common stock (the “Company Shares”) to the Sellers. The transaction was consummated on May 13, 2024. On May 30, 2024, GK Partners exercised a portion of its warrant for <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240530__20240530__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GKPartnersMember_ztllz2CsE2oj">3,000 shares. The exercise price was $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240530__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GKPartnersMember_zy5HnNxdlka7">10.00 per share for total proceeds of $30,000. Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of the Company, and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors. Mr. Hill-Madsen will continue as Chairman of the Board of Orocidin A/S, of which the Company recently acquired <span id="xdx_902_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20240516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--OrocidinASMember_zfYBr7GCNjYl" title="Equity interest acquired, percentage">95% of the outstanding shares in exchange for shares of the Company. On June 3, 2024, the Company’s Board of Directors approved a compensation plan under which the Chairman of the Board of Directors will receive compensation of $<span id="xdx_90A_eus-gaap--OfficersCompensation_c20240603__20240603__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoa7qD59OXvb" title="Officers compensation">20,000 per annum, and each other Director will receive compensation of $<span id="xdx_900_eus-gaap--OfficersCompensation_c20240603__20240603__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zR43YgRQzIL8" title="Officers compensation">10,000 per annum, in consideration of their serving on the Corporation’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms. On June 7, 2024, the Company’s Board of Directors and stockholders holding a majority of the outstanding shares of common stock approved the Company’s 2024 Stock Incentive Plan providing for the issuance of up to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwentyTwentyFourStockIncentivePlanMember_zI4Z0fN9lqRb" title="Common stock authorized for issuance">7,000,000 shares of Common Stock for issuance in connection with stock option awards thereunder. On November 8, 2024, the Company effectuated a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20241108__20241108__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHEDIuD0eQVf" title="Reverse stock split">1:10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the “Reverse Stock Split”). The Reverse Stock Split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value will remain unchanged at $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241108__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1b89MEej069" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241108__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zb0jAx02QfMl" title="Common stock, par value">0.001, respectively. All common stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these consolidated financial statements and related disclosures.

3000

10.00

30000

525597

0.950

3800000

3000

10.00

30000

0.95

20000

10000

7000000

1:10 reverse stock split

0.001

46131

49933

72338

118469

49933

10014 7640

223316

41424

18641985

1750000

20785208

1807573

145368

5019

7500

13886

152868

26405

152868

26405

0.001

50000000

4965626

1110226

4966 1110

154

30328

64333434

45696761

13693

-2848

-44642481

-43883527

19679284

1781168

953056

20632340

1781168

20785208

1807573

2500

49104

30593

98546

57593

46428

56868

72210

76793

150000

71154

9420

104099

14084

343209

509895

96881

768064

148470

-507395

-96881

-765564

-148470

-1909

9384

-1

-1909

-1

9384

-507396

-98790

-765565

-139086

-507396

-98790

-765565

-139086

-6611

-500785

-98790

-758954

-139086

16771

-3104

16541

-3165

-484014

-101894

-742413

-142251

-0.10

-0.09

-0.19

-0.14

4960079

1084665

4050313

972283

1110226

1110

45696761

-43883527

-30328

-2848

1781168

3800000

3800

18046200

18050000

6000 6 59994 60000 60000

30000

138949

138979

13886 13886 13886 950000 950000

-258169

-230

4946226

4946

63955790

-44141696

-30328

-3078

19785634

950000

20735634

19400 19 193981 194000 194000

183663

9667

193330

-500785

-6611

-507396

16771

4965626

4966

64333434

-44642481

-30328

13693

19679284

953056

20632340

829626

830

42254155

-42197663

-30328

665

27658

250000

250

1749750

1750000

25000 25000

-40296

-61

1079626

1080

44003905

-42237959

-30328

25000

604

1762301

1079626

1080

44003905

-42237959

-30328

25000

604

1762301

8000 8 79992 80000

-98790

-3104

1087626

1088

44083897

-42336749

-30328

25000

-2500

1740407

1087626

1088

44083897

-42336749

-30328

25000

-2500

1740407

-765565

-139086

138979

-7500

42431

1932

-44481

41424

110570

8528

7500

-12127

-599871

-100136

2374

134572

132198

1924

193330

254000

105000

447330

106924

-20343

6788

16541

-3165

49933

7149

46131

10772

1750000

18050000 13886

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Nordicus Partners Corporation (the “Company” or “Nordicus”) was founded in 1993 as a subsidiary of PolyMedica Corporation. On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provided critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states. As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify either an (i) operating company to acquire or merge with through an equity-based exchange transaction or (ii) investor interested in purchasing a majority interest in our common stock, whereby either transaction would likely result in a change in control. On March 3, 2020, we filed a Certificate of Amendment to the Company’s Certificate of Incorporation, which amendment was unanimously approved by our Board of Directors, to change our name from AdvanSource Biomaterials Corporation to EKIMAS Corporation. On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”) providing for the purchase of a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211011__20211012__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zLTYcfwRq8h5" title="Number of shares issued">511,448 of our common stock, on a post-split basis, or approximately <span id="xdx_902_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20211011__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z0JzJS9JLxya" title="Percentage of outstanding common stock">90% of our total shares of common stock outstanding for total cash consideration of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211011__20211012__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z6UanHBzMlW7" title="Cash consideration for shares">400,000. Reddington purchased in two tranches on October 12, 2021 and March 15, 2022. Pursuant to the SPA, the Company effectuated a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20220310__20220311__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_zE269bRTxpL6" title="Reverse stock split">1-for 50 reverse stock split on March 11, 2022 (the “Reverse Split”). Accordingly, on a post-split basis, the shares purchased in connection with the First Closing resulted in Reddington owning <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220310__20220311__srt--StatementScenarioAxis__custom--FirstClosingMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zGaf8wdOERya" title="Stock issued during period, shares, new issues">42,273 shares of our common stock. As set forth in the SPA, Reddington then purchased from us on March 15, 2022, an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220314__20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__srt--StatementScenarioAxis__custom--SecondClosingMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zUiW9UBER6a9" title="Stock issued during period, shares, new issues">469,175 shares of our common stock, on a post-split basis (the “Second Closing”). After the issuance thereof Reddington owned <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220315__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zx1lFXmAMZL9" title="Common stock owned">511,448 shares of our common stock, or approximately <span id="xdx_90C_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20220314__20220315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--ReddingtonPartnersLLCMember_z9kTyUsEDCp4" title="Percentage of outstanding common stock">90% of our total shares of common stock outstanding. On February 23, 2023, the Company and Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S), a Danish stock corporation, consummated the transactions contemplated by that certain Contribution Agreement (the “Contribution Agreement”) by and among the Company, Nordicus, GK Partners ApS (“GK Partners”), Henrik Rouf and Life Science Power House ApS (“LSPH”). (GK Partners, Rouf and LSPH are collectively referred to herein as the “Sellers”, and each individually as a “Seller”). Pursuant to the Contribution Agreement the Sellers contributed, transferred, assigned and conveyed to the Company all right, title and interest in and to one hundred percent (<span id="xdx_901_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20230223__20230223__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_zhPt8mAnyDee" title="Percentage of outstanding common stock">100%) of the issued and outstanding capital stock of Nordicus for an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230223__20230223__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_zFkXKmiHGVd" title="Stock issued during period, shares, new issues">250,000 shares of the Company’s common stock, par value $0.001 per share. As a result of this transaction, Nordicus became a <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NordicusPartnersAsMember__us-gaap--TypeOfArrangementAxis__custom--ContributionAgreementMember_zfNQWEsHjac7" title="Ownership percentage">100% wholly owned subsidiary of the Company. On February 23, 2023, Tom Glaesner Larsen and Christian Hill Madsen were appointed directors of the Company. Mr. Hill-Madsen will continue as Chairman of the Board of Orocidin A/S, of which the Company recently acquired 95% of the outstanding shares in exchange for shares of the Company. On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On June 1, 2023, the Company acquired a <span id="xdx_90C_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20230601__us-gaap--BusinessAcquisitionAxis__custom--MagMileCapitalIncMember_zTZKDTZXr8Hi" title="Equity interest acquired, percentage">4.99% interest in Mag Mile Capital, Inc., a full-service commercial real estate mortgage banking firm headquartered in Chicago with offices in the states of New York, Massachusetts, Connecticut, Florida, Texas and Nevada. Mag Mile Capital is a national platform comprised of capital markets specialists with extensive experience in real estate bridge financing, mezzanine and permanent debt placement and equity arrangements throughout the full capital stack and across all major real estate asset classes nationwide, including hotels, multifamily, office, retail, industrial, healthcare, self-storage and special purpose properties, offering access to structured debt and equity advisory solutions and placement for real estate investors, developers, and entrepreneurs, On June 9, 2023, Tom Glaesner Larsen resigned from the Company’s board of directors, and the remaining board members appointed Henrik Keller as his replacement. On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. On May 13, 2024, the Company and certain shareholders of Orocidin A/S (the “Orocidin Sellers”), a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Orocidin Sellers sold to the Company <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240513__20240513__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU2FAIO02hIj" title="Restricted Shares issued">525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing <span id="xdx_90D_ecustom--PercentageOfOutstandingCommonStock_pid_dp_uPure_c20240513__20240513__dei--LegalEntityAxis__custom--OrocidinASMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4xHEoY39n5i" title="Outstanding shares percentage">95.0% of Orocidin’s outstanding shares of capital stock. In exchange, the Company issued <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240513__20240513__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMx1H0PGUhT5" title="Number of shares issued">3,800,000 restricted shares of its common stock (the “Company Shares”) to the Orocidin Sellers. The transaction was consummated on May 13, 2024. Orocidin A/S, is a clinical-stage biopharmaceutical company which is advancing the next generation of periodontitis therapies. On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement.

7250000

511448

0.90

400000

1-for 50 reverse stock split

42273

469175

511448

0.90 1

250000

0.001

0.95

0.0499

525597

0.950

3800000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company’s unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six months ending September 30, 2024, and not necessarily indicative of the results to be expected for the full year ending March 31, 2025. These unaudited financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024. Reverse Stock Split On November 8, 2024, the Company effectuated a 1:10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the “Reverse Stock Split”). The Reverse Stock Split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value will remain unchanged at $0.001, respectively. All common stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these consolidated financial statements and related disclosures. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, and impairment in fair value of goodwill. Concentration of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We also maintain cash in foreign bank accounts that are not federally insured. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Cash and Cash Equivalents Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of September 30, 2024 and March 31, 2024. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, Managementselskabet af 12.08.2020 A/S and Orocidin A/S. All significant intercompany transactions have been eliminated in consolidation. Translation Adjustment The accounts of the Company’s subsidiaries are maintained in Danish krone. According to Accounting Standards Codification (“ASC”) 830 Foreign Currency Matters, all assets and liabilities were translated at the current exchange rate at respective balance sheets dates, stockholders’ equity are translated at the historical rates and statement of operations items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive loss in accordance with the Comprehensive Income Topic of the Codification (ASC 220), as a component of Stockholders’ equity. Transaction gains and losses are reflected in the statements of operations. Comprehensive Loss The Company uses the Statement of Financial Accounting Standards (“SFAS”) 130 “Reporting Comprehensive Income” (ASC Topic 220). Comprehensive income is comprised of net income and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income is included in net loss and foreign currency translation adjustments. Research and Development Costs Research and development expense consists primarily of costs associated with Orocidin’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Stock-based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures of grants as they occur. Compensation cost for awards is recognized using the straight-line method over the vesting period. Stock-based compensation is included in general and administrative and research and development expense in the consolidated statements of operations and comprehensive loss. Refer to Note 8 for details on the stock incentive plan established during the three months ended June 30, 2024. Through the six months ended September 30, 2024, the Company has not granted any awards qualifying as stock-based compensation under this plan. During the six months ended September 30, 2024, the Company issued 30,000 shares of common stock to a third party for consulting services unrelated to the stock incentive plan. Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity of those instruments. Net Income (Loss) Per Common Share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. As of September 30, 2024 and 2023, there were 607,500 and 653,000 potentially dilutive shares of common stock from warrants, respectively. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share. Goodwill The Company accounts for business combinations under the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. The Company tests for indefinite-lived intangibles and goodwill impairment as of its fiscal year end, March 31, each year and whenever events or circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. Indefinite-lived Intangible Assets The Company accounts for its indefinite-lived intangible assets in accordance with ASC 350, Intangibles - Goodwill and Other. Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain assets acquired via the Company’s business combination with Orocidin A/S detailed in Note 9, for impairment by comparing their fair values to their carrying values. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values. Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> In January 2024, the Company signed an agreement with Orocidin for which it recognized revenue in the fiscal year ended March 31, 2024. Since Orocidin became a subsidiary in the first quarter ended June 30, 2024, no more revenue is to be recognized, but will be eliminated as an intercompany transaction. Non-controlling Interests In accordance with ASC 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. The Company has determined that Orocidin A/S is a VIE, and that the Company is the primary beneficiary. While the Company owns 95% of Orocidin A/S’s equity interests, the remaining equity interests in Orocidin A/S are owned by unrelated third parties, and the agreement with these third parties provides the Company with greater voting rights. Accordingly, the Company consolidates its interest in the financial statements of Orocidin A/S under the VIE rules and reflects the third parties’ interests in the unaudited consolidated financial statements as a non-controlling interest. The Company records this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests are not redeemable by the equity holders and are presented as part of permanent equity. Income and losses are allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity. Refer to Note 9 (“Business Combinations”) for more information regarding non-controlling interest recognized related to the Orocidin A/S business combination. Recently Issued Accounting Pronouncements The Company has implemented all new applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Basis of Presentation The Company’s unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six months ending September 30, 2024, and not necessarily indicative of the results to be expected for the full year ending March 31, 2025. These unaudited financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024.

Reverse Stock Split On November 8, 2024, the Company effectuated a 1:10 reverse stock split of its issued and outstanding common stock, rounding up to account for any fractional shares (the “Reverse Stock Split”). The Reverse Stock Split had no effect on the Company’s authorized shares of common stock or preferred stock and the par value will remain unchanged at $0.001, respectively. All common stock share, warrant and per share amounts (except our authorized but unissued shares) have been retroactively adjusted in these consolidated financial statements and related disclosures.

1:10 reverse stock split

0.001

Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, and impairment in fair value of goodwill.

Concentration of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We also maintain cash in foreign bank accounts that are not federally insured. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.

Cash and Cash Equivalents Cash amounts include cash on hand and cash on deposit with banks. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of September 30, 2024 and March 31, 2024.

Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, Managementselskabet af 12.08.2020 A/S and Orocidin A/S. All significant intercompany transactions have been eliminated in consolidation.

Translation Adjustment The accounts of the Company’s subsidiaries are maintained in Danish krone. According to Accounting Standards Codification (“ASC”) 830 Foreign Currency Matters, all assets and liabilities were translated at the current exchange rate at respective balance sheets dates, stockholders’ equity are translated at the historical rates and statement of operations items are translated at the average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive loss in accordance with the Comprehensive Income Topic of the Codification (ASC 220), as a component of Stockholders’ equity. Transaction gains and losses are reflected in the statements of operations.

Comprehensive Loss The Company uses the Statement of Financial Accounting Standards (“SFAS”) 130 “Reporting Comprehensive Income” (ASC Topic 220). Comprehensive income is comprised of net income and all changes to the consolidated statements of stockholders’ equity, except changes in paid-in capital and distributions to shareholders. Comprehensive income is included in net loss and foreign currency translation adjustments.

Research and Development Costs Research and development expense consists primarily of costs associated with Orocidin’s ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received.

Stock-based Compensation The Company accounts for stock-based compensation using the provisions of ASC 718, Stock-Based Compensation, which requires the recognition of the fair value of stock-based compensation. Stock-based compensation is estimated at the grant date based on the fair value of the awards. The Company accounts for forfeitures of grants as they occur. Compensation cost for awards is recognized using the straight-line method over the vesting period. Stock-based compensation is included in general and administrative and research and development expense in the consolidated statements of operations and comprehensive loss. Refer to Note 8 for details on the stock incentive plan established during the three months ended June 30, 2024. Through the six months ended September 30, 2024, the Company has not granted any awards qualifying as stock-based compensation under this plan. During the six months ended September 30, 2024, the Company issued 30,000 shares of common stock to a third party for consulting services unrelated to the stock incentive plan.

30000

Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB ASC for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr> </table> The carrying amount of the Company’s financial assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity of those instruments.

Net Income (Loss) Per Common Share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. As of September 30, 2024 and 2023, there were 607,500 and 653,000 potentially dilutive shares of common stock from warrants, respectively. Diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

607500

653000

Goodwill The Company accounts for business combinations under the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations, where the total purchase price is allocated to the tangible and identified intangible assets acquired and liabilities assumed based on their estimated fair values. The purchase price is allocated using the information currently available, and may be adjusted, up to one year from acquisition date, after obtaining more information regarding, among other things, asset valuations, liabilities assumed and revisions to preliminary estimates. The purchase price in excess of the fair value of the tangible and identified intangible assets acquired less liabilities assumed is recognized as goodwill. The Company tests for indefinite-lived intangibles and goodwill impairment as of its fiscal year end, March 31, each year and whenever events or circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable.

Indefinite-lived Intangible Assets The Company accounts for its indefinite-lived intangible assets in accordance with ASC 350, Intangibles - Goodwill and Other. Indefinite-lived intangible assets are not amortized but instead are reviewed for impairment annually, or more frequently if an event occurs or circumstances change which indicate that an asset might be impaired. Pursuant to ASC 350, the Company tests its indefinite-lived intangible assets, which consist of certain assets acquired via the Company’s business combination with Orocidin A/S detailed in Note 9, for impairment by comparing their fair values to their carrying values. An impairment charge is recorded if the estimated fair value of such assets has decreased below their carrying values.

Revenue Recognition The Company recognizes revenue under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of a contract with a customer;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when or as the performance obligations are satisfied.</td></tr> </table> In January 2024, the Company signed an agreement with Orocidin for which it recognized revenue in the fiscal year ended March 31, 2024. Since Orocidin became a subsidiary in the first quarter ended June 30, 2024, no more revenue is to be recognized, but will be eliminated as an intercompany transaction.

Non-controlling Interests In accordance with ASC 810, Consolidation, the Company assesses whether it has a variable interest in legal entities in which it has a financial relationship and, if so, whether or not those entities are variable interest entities (“VIEs”). For those entities that qualify as VIEs, ASC 810 requires the Company to determine if the Company is the primary beneficiary of the VIE, and if so, to consolidate the VIE. If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. The Company has determined that Orocidin A/S is a VIE, and that the Company is the primary beneficiary. While the Company owns 95% of Orocidin A/S’s equity interests, the remaining equity interests in Orocidin A/S are owned by unrelated third parties, and the agreement with these third parties provides the Company with greater voting rights. Accordingly, the Company consolidates its interest in the financial statements of Orocidin A/S under the VIE rules and reflects the third parties’ interests in the unaudited consolidated financial statements as a non-controlling interest. The Company records this non-controlling interest at its initial fair value, adjusting the basis prospectively for the third parties’ share of the respective consolidated investments’ net income or loss or equity contributions and distributions. These non-controlling interests are not redeemable by the equity holders and are presented as part of permanent equity. Income and losses are allocated to the non-controlling interest holders based on its economic ownership percentage. Transactions with non-controlling interests that do not result in a loss of control are accounted for as equity transactions. Any difference between the fair value of the consideration paid or received and the carrying amount of the non-controlling interest is recognized in equity. Refer to Note 9 (“Business Combinations”) for more information regarding non-controlling interest recognized related to the Orocidin A/S business combination.

0.95

Recently Issued Accounting Pronouncements The Company has implemented all new applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed. In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“DISE”), which will require additional disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The new standard will be effective for public companies for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact of this accounting standard update on its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN The Company’s unaudited consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has no revenue and has incurred losses since inception resulting in an accumulated deficit of $44,642,481 as of September 30, 2024. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, there is substantial doubt about the ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company’s recent acquisition, its generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand, the private placement of common stock and the exercise of outstanding warrants. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

-44642481

NOTE 4 - INVESTMENTS On June 20, 2023, the Company and GK Partners ApS entered into a Stock Purchase and Sale Agreement, under which GK Partners ApS sold to the Company <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zX88QY6Z3CQ2" title="Number of shares issued">5,000,000 restricted shares of common stock of Mag Mile Capital, Inc. The shares were restricted in that they were subject to a registration statement filed on Form S-1 by Mag Mile Capital on September 6, 2023. The Form S-1 became effective on July 5, 2024, removing the restriction on the shares. In exchange, the Company issued <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zRl4TIZX5sc7" title="Number of shares issued">250,000 restricted shares of its common stock to GK Partners ApS. The shares were valued at $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z2E3llp3UGvj" title="Stock issued during period, value">1,750,000, using $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlrO3WqGCEFk" title="Common stock price per share">7.00 per share, the closing stock price for the Company’s common stock on the last business day before the agreement. The Company accounts for its investment under the guidance of ASC 321, Investments – Equity Securities, which provides guidance for equity interests that meet the definition of an equity security. Equity interests with readily determinable fair values are carried at fair value with changes in value recorded in earnings. There currently is no active market for the shares of Mag Mile Capital, Inc, therefore, the investment remains at cost until such time there is an established fair value of Mag Mile Capital, Inc’s shares to be used to adjust the value of the Company’s investment in those shares. The Company’s investment in Mag Mile Capital, Inc is subject to changes and fluctuations based on their business activities and their ability to trade in the future.

5000000

250000

1750000

7.00

NOTE 5 - RELATED PARTY TRANSACTIONS Mr. Tom Glasner Larsen is an affiliate of GK Partners and was a member of our board of directors from February 23, 2023, until his voluntary retirement on June 9, 2023. He was a beneficial owner of a controlling interest in Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S) until its acquisition by us on February 23, 2023. He was also a beneficial owner of a controlling interest in Orocidin A/S until its acquisition by us on May 13, 2024. On April 11, 2022, effective April 1, 2022, we issued to GK Partners, for financial services, a warrant to immediately purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zZfDFXVFDQSl" title="Warrant to purchase common stock">600,000 shares of our common stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zYvtozSvax7i" title="Exercise price of warrants">10.00 per share, which expired on <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_z20Kuy4VBNbb" title="Warrant expiration date">December 31, 2023. On December 22, 2023, the expiration date of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zHi5zJUKxMv1" title="Number of remaining warrants">570,500 remaining warrant shares was extended to <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zOzfYDuQ0U47" title="Expiration date, warrants">December 31, 2024. During the year ended March 31, 2024, GK Partners exercised a portion of its warrant for a total of <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20230401__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zPu8VNexgdug" title="Shares issued in exercise of warrants">30,600 shares. The exercise price was $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zhCPFn8hF6xj" title="Exercise price per share">10.00 per share for total proceeds of $306,000. During the quarter ended June 30, 2024, GK Partners exercised a portion of its warrant for <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240401__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zoHBLLGLZBUb" title="Shares issued in exercise of warrants">6,000 shares. The exercise price was $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zdltKms7p84j" title="Exercise price per share">10.00 per share for total proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_c20240401__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_ztHsdmuX4BBl" title="Proceeds from warrant exercises">60,000. During the quarter ended September 30, 2024, GK Partners exercised a portion of its warrant for <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zOxh0ewgBYM2" title="Shares issued in exercise of warrants">19,400 shares. The exercise price was $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWGbrC0NCola" title="Exercise price per share">10.00 per share for total proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpMtH8uw3Jlg" title="Proceeds from warrant exercises">194,000. On February 23, 2023, pursuant to the Contribution Agreement by and among the Company, Managementselskabet af 12.08.2020 A/S (formerly Nordicus Partners A/S), GK Partners, Henrik Rouf and LSPH, were issued 250,000 shares of the common stock (Note 1). On June 20, 2023, the Company and GK Partners ApS (the “Seller”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Seller sold to the Company <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__dei--LegalEntityAxis__custom--MagMileCapitalIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1q6hOgJzDj6" title="Shares issued">5,000,000 restricted shares of common stock of Mag Mile Capital, Inc. In exchange, the Company issued <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230619__20230620__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zNNbNbH3saeg" title="Shares issued">250,000 restricted shares of its common stock to the Seller. Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services (the “Affiliate”). We recorded legal fees to the Affiliate of $20,852 and $8,603 for the three months ended September 30, 2024 and 2023, respectively, and $38,634 and $19,527 for the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, we had no outstanding payable due to the Affiliate for either period. Our employment agreement with Henrik Rouf, our chief executive officer, provided for a base salary of $72,000 per year, commencing April 1, 2023, and had a term of one year. On April 8, 2024 the agreement was amended to increase Mr. Rouf’s annual salary to $120,000 and to extend the term to <span id="xdx_903_ecustom--EmploymentAgreementExpirationDate_pid_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HenrikRoufMember_zQ1NqlKjfHu3" title="Employment agreement expiration date">April 1, 2025. Our consulting agreement with Bennett Yankowitz, our chief financial officer and a member of our board of directors, provided for a base salary of $36,000 per year, commencing April 1, 2023, and had a term of <span id="xdx_902_ecustom--EmploymentAgreementTerm_dc_c20230401__20230401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_zpLnofsA4E3c" title="Employment agreement term">one year. On April 8, 2024 the agreement was amended to increase Mr. Yankowitz’s annual salary to $60,000 and to extend the term to <span id="xdx_90A_ecustom--EmploymentAgreementExpirationDate_dd_c20240408__20240408__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrBennettYankowitzMember_zOuDaqokmTtk" title="Employment agreement expiration date">April 1, 2025. During the six months ended September 30, 2024, a related party forgave their payable of $13,886. The amount has been credited to additional paid in capital. Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of the Company, and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors. Mr. Hill-Madsen will continue as Chairman of the Board of Orocidin A/S, of which the Company recently acquired 95% of the outstanding shares in exchange for shares of the Company. On June 3, 2024, the Company’s Board of Directors approved a compensation plan under which the Chairman of the Board of Directors will receive compensation of $20,000 per annum, and each other Director will receive compensation of $10,000 per annum, in consideration of their serving on the Corporation’s Board of Directors, payable in equal installments semiannually in arrears, commencing December 31, 2024, without proration for partial terms.

600000

10.00

2023-12-31

570500

2024-12-31

30600

10.00

306000

6000

10.00

60000

19400

10.00

194000

250000

5000000

250000

20852

8603

38634

19527

72000

P1Y

120000

2025-04-01

36000

P1Y

60000

2025-04-01 13886

0.95

20000

10000

NOTE 6 - PREFERRED STOCK Preferred Stock We have authorized 5,000,000 shares, $0.001 par value, Preferred Stock (the Preferred Stock”) of which 500,000 shares have been issued and redeemed, therefore are not considered outstanding. In addition, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zBFAjserIYW9" title="Preferred stock shares authorized">500,000 shares of Preferred Stock have been designated as Series A Junior Participating Preferred Stock (the “Junior Preferred Stock”) with the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions specified in the Certificate of Designation of the Junior Preferred Stock filed with the Delaware Department of State on January 28, 2008. Such number of shares may be increased or decreased by resolution of the Board of Directors; provided, that no decrease shall reduce the number of shares of Junior Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by us that is convertible into Junior Preferred Stock. Each share of Junior Preferred Stock shall entitle the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. The holders of shares of Junior Preferred Stock, in preference to the holders of the Company’s Common Stock and of any other junior stock, shall be entitled to receive, when and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash. Upon the Company’s liquidation, dissolution or winding up, no distribution shall be made to the holders of shares of stock ranking junior to the Junior Preferred Stock unless, prior thereto, the holders of shares of Junior Preferred Stock shall have received $100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon. The Junior Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of Preferred Stock. As of September 30, 2024 and March 31, 2024, there are <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQrA1qEmm6zi" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDOKBrUa1R3" title="Preferred stock, shares outstanding">no shares of Junior Preferred Stock or undesignated Preferred Stock issued and outstanding.

5000000

0.001

500000

100

NOTE 7 - COMMON STOCK TRANSACTIONS The Company is authorized to issue 50,000,000 shares of Common Stock with a par value of $0.001 per share. Holders of the Company’s Common Stock are entitled to one vote for each share. During the six months ended September 30, 2024, GK Partners exercised a portion of its warrant for <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240401__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zJ7qGsg7j7q1" title="Shares issued in exercise of warrants">25,400 shares. The exercise price was $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zb5KP5MJbEs" title="Exercise price per share">10.00 per share for total proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20240401__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_za5LqwIW8CTh" title="Proceeds from warrant exercises">254,000. During the six months ended September 30, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240401__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GKPartnersMember_zkKqegwwWKFb" title="Shares issued for service, share">30,000 shares of common stock for services. The value of the shares issued resulted in a total non-cash expense of $138,979. On May 13, 2024, the Company and certain shareholders of Orocidin A/S, a Danish stock corporation entered into a Stock Purchase and Sale Agreement, under which the Company issued <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240513__20240513__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYQtrC4cODtl" title="Number of shares issued">3,800,000 restricted shares of its common stock to the Sellers (Note 1). During the three months ended September 30, 2024, Orocidin A/S issued shares of its common stock in a capital raise with a third party in exchange for proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember_zyzLhUbM7Yyj" title="Issuance of common stock">193,330. Aligned with the Company’s ownership interest in Orocidin A/S, 5% of the proceeds, or $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember_zgJyJMiR7I06" title="Issuance of common stock">9,667, was allocated to noncontrolling interests while 95% of the proceeds, or $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OrocidinASMember_zNaAGSl0K844" title="Issuance of common stock">183,663, was allocated to additional paid in capital.

50000000

0.001

25400

10.00

254000

30000

138979

3800000

193330

0.05

9667

0.95

183663

NOTE 8 - STOCK-BASED COMPENSATION The Company established the Nordicus Partners Corporation 2024 Stock Incentive Plan (the “Plan”). This plan was effective on June 7, 2024 per the board of directors resolution. The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key people with incentives to improve stockholder value and to contribute to the growth and financial success of the Company, and (ii) enabling the Company to attract, retain and reward the best-available persons. The Plan permits the granting of stock options (including incentive stock options qualifying under Code Section 422 and nonqualified stock options), stock appreciation rights (SARs), restricted or unrestricted stock awards, restricted stock units, performance awards, other stock-based awards, or any combination of the foregoing. Participation in the Plan shall be open to all employees, officers, directors, and consultants of the Company, or of any affiliate of the Company, as may be selected by the Company from time to time. However, only employees of the Company, and of any parent or subsidiary of the Company, shall be eligible for the grant of an incentive stock option. The grant of an award at any time to any person shall not entitle that person to a grant of an award at any future time. The shares of Common Stock that may be issued with respect to awards granted under the Plan shall not exceed an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOXPDzcbfdBk" title="Shares of common stock">7,000,000 shares of Common Stock. The maximum number of shares of Common Stock under the Plan that may be issued as incentive stock options shall be <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmSVjggfdwxf" title="Stock options">7,000,000 shares. Regarding performance-based award limitations, the number of shares of Common Stock that may be granted in the form of options, SARs, restricted stock awards, restricted stock units, or performance award shares in a single fiscal year to a participant may not exceed <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240607__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zn5dEF78iCAg" title="Restricted stock awards, shares">2,000,000 of each form. As of September 30, 2024, no stock awards of any form have been granted under this plan. On June 17, 2024, the Company’s board of directors cancelled the Company’s 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”). At the time there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_do_c20240617__20240617__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztQ19E4Qiuf5" title="Stock awards">no stock awards of any kind outstanding under the 2017 Plan.

7000000

2000000

NOTE 9 - BUSINESS COMBINATION On May 13, 2024, the Company and certain shareholders of Orocidin A/S, a Danish stock corporation entered into a Stock Purchase and Sale Agreement (“Business Combination”), under which the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240513__20240513__us-gaap--BusinessAcquisitionAxis__custom--DanishStockCorporationMember_zGFPZNk4O4v1" title="Number of share issued for acquisitions">3,800,000 restricted shares of its common stock to the Sellers. The shares were valued at $5.00, the closing stock price on the date of acquisition. The Company accounted for the transaction as a business combination under ASC 805 and as a result, allocated the fair value of identifiable assets acquired and liabilities assumed as of the acquisition date as outlined in the table below. The excess of the purchase price over the estimated fair values of the underlying identifiable assets acquired, liabilities assumed was allocated to goodwill. <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_z1dDb7RQovc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The allocation of the purchase price and the estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interest are shown below: SCHEDULE OF PURCHASE PRICE AND ESTIMATED MARKET VALUE OF THE ASSETS ACQUIRED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr id="xdx_404_eus-gaap--BusinessCombinationConsiderationTransferredAbstract_iB_z1pQIh0mtZdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Consideration</td><td> </td> <td colspan="2" id="xdx_49D_20240513__us-gaap--BusinessAcquisitionAxis__custom--DanishStockCorporationMember_zAXFRcnXNcv3"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Consideration issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240513__20240513__us-gaap--BusinessAcquisitionAxis__custom--DanishStockCorporationMember_z5BbDAd8Hjb2" style="width: 16%; text-align: right" title="Consideration issued">18,050,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_iB_zebsPOWqs7L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Identified assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z4d0tIw8zEgc" style="vertical-align: bottom; background-color: White"> <td>Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zhbX30eUrNq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_iI_zUdCAT53Wb34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,906</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruals_iI_zKRMAAmsMkIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts payable and accruals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(29,779</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_ztAo1rJSVLi1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total identified assets, liabilities, and noncontrolling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">358,015</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNoncontrollingInterest_iI_z7Wge5PcjU2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">950,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Goodwill_iI_zU36f9izxiZd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Excess purchase price allocated to goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,641,985</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> From the closing date of the Business Combination through September 30, 2024, Orocidin A/S has incurred $40,693 in net losses.

3800000

5.00

<p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_z1dDb7RQovc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The allocation of the purchase price and the estimated fair values of the assets acquired, liabilities assumed, and noncontrolling interest are shown below: SCHEDULE OF PURCHASE PRICE AND ESTIMATED MARKET VALUE OF THE ASSETS ACQUIRED LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr id="xdx_404_eus-gaap--BusinessCombinationConsiderationTransferredAbstract_iB_z1pQIh0mtZdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic">Consideration</td><td> </td> <td colspan="2" id="xdx_49D_20240513__us-gaap--BusinessAcquisitionAxis__custom--DanishStockCorporationMember_zAXFRcnXNcv3"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Consideration issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationConsiderationTransferred1_c20240513__20240513__us-gaap--BusinessAcquisitionAxis__custom--DanishStockCorporationMember_z5BbDAd8Hjb2" style="width: 16%; text-align: right" title="Consideration issued">18,050,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_iB_zebsPOWqs7L3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: left">Identified assets and liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z4d0tIw8zEgc" style="vertical-align: bottom; background-color: White"> <td>Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zhbX30eUrNq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223,316</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherReceivables_iI_zUdCAT53Wb34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,906</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruals_iI_zKRMAAmsMkIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accounts payable and accruals</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(29,779</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_ztAo1rJSVLi1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total identified assets, liabilities, and noncontrolling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">358,015</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNoncontrollingInterest_iI_z7Wge5PcjU2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">950,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Goodwill_iI_zU36f9izxiZd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Excess purchase price allocated to goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,641,985</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

18050000

134572

223316

29906 -29779

358015

950000

18641985

40693

NOTE 10 - WARRANTS A summary of the Company’s outstanding warrants as of September 30, 2024 is as follows. SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"></td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weight</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining Contract</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding, March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zv67fG0DQQyc" style="width: 12%; text-align: right" title="Number of Warrants, Beginning balance">632,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_z23SYcWPkbed" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_z0sXtdXNlhe1" title="Weighted Average Remaining Contractual term,Outstanding">1.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zzY9yqaI27fl" style="width: 12%; text-align: right" title="Intrinsic Value, Beginning balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zYpPyg9avm2d" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zZxvlO7jKtXd" style="text-align: right" title="Number of Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zANCQJUnDrt3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(25,400</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zSe5wFxLRJq1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zUtkNHIj4BU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Ending balance">607,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_ztPL4gq6V5J5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zHHwB2pdk1qh" title="Weighted Average Remaining Contractual term,Outstanding">0.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zoVXhNDI2tI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Ending balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

A summary of the Company’s outstanding warrants as of September 30, 2024 is as follows. SCHEDULE OF WARRANT ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"></td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weight</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining Contract</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Term</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Outstanding, March 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zv67fG0DQQyc" style="width: 12%; text-align: right" title="Number of Warrants, Beginning balance">632,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_z23SYcWPkbed" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_z0sXtdXNlhe1" title="Weighted Average Remaining Contractual term,Outstanding">1.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zzY9yqaI27fl" style="width: 12%; text-align: right" title="Intrinsic Value, Beginning balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zYpPyg9avm2d" style="text-align: right" title="Number of Warrants, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zZxvlO7jKtXd" style="text-align: right" title="Number of Warrants, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zANCQJUnDrt3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(25,400</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zSe5wFxLRJq1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Exercised">10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zUtkNHIj4BU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Ending balance">607,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_ztPL4gq6V5J5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zHHwB2pdk1qh" title="Weighted Average Remaining Contractual term,Outstanding">0.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20240401__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--ReverseStockSplitMember_zoVXhNDI2tI4" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Ending balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

632900

10 P1Y4M6D

25400

607500

10 P0Y7M13D

NOTE 11 - SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has determined that it has the following material subsequent events to disclose in these financial statements. Subsequent to September 30, 2024, GK Partners exercised a portion of its warrant for a total of <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20241001__20241114__dei--LegalEntityAxis__custom--GKPartnersMember_zGNCWjsEhdPg" title="Common stock issued on exercise of warrants">22,200 shares. The exercise price was $10.00 per share for total proceeds of $222,000. On November 11, 2024, the Company announced that it entered into an agreement with Bio-Convert ApS (“Bio-Convert”) to <span id="xdx_905_eus-gaap--ConversionOfStockDescription_c20241111__20241111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--RestrictedCommonStockMember_z4SEFXYXAj1a" title="Stock conversion, description">acquire 100% of the outstanding shares of Bio-Convert in exchange for <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_pn6n6_c20241111__20241111__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--RestrictedCommonStockMember_z3cBFdnWbiSh" title="Outstanding shares, converted">12 million shares of the Company’s restricted common stock. Bio-Convert is a Denmark-based clinical-stage biopharmaceutical company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and cause oral cancer. Bio-Convert is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation. On November 12, 2024, the Company announced that it entered into an agreement with Orocidin A/S to acquire the remaining <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFareFJWB8Z4" title="Number of shares of stock issued to acquisitions">29,663 outstanding shares, or approximately 5%, of Orocidin A/S. In exchange, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241112__20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6uk6gDxLyq2" title="Restricted stock award, gross">200,000 shares of restricted common stock to the selling shareholders of Orocidin. Upon closing of the acquisition, Orocidin A/S became a 100% wholly owned subsidiary of the Company.

22200

10.00

222000

acquire 100% of the outstanding shares of Bio-Convert in exchange for 12 million shares

12000000

29663

200000